46. Estey E, Wang X-M, Thall P, et al.: Plausibility of delaying induction therapy in untreated AML. Blood 104:879a, Abstract, 2004.

47. Bishop JF, Matthews JP, Young GA, et al.: Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 28:315-327, 1998.

48. Kolitz J, George S, Dodge R, et al.: Dose escalation studies of daunorubicin, ara-C, and etoposide with and without multidrug resistance modulation with PSC 833 in untreated adults with AML <60 years [abstract]. Blood 98(11):175a, 2001.

49. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989.

50. Estey EH, Thall PF: New designs for phase 2 clinical trials. Blood 102:442-448, 2003.

51. Thall PF, Simon RM, Estey EH: Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 14:357-379, 1995.

52. Thall PF, Simon RM, Estey EH: New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 14:296-303, 1996.

53. Thall PF, Sung H-G, Estey EH: Selecting therapeutic strategies based on efficacy and death in multicourse clinical trials. J Am Stat Assoc 97:29-39, 2002.

54. Inoue LY, Thall PF, Berry DA: Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58:823-831, 2002.

55. Berry DA: Statistical innovations in cancer research. In: Holland J, Frei T, et al. (eds.) Cancer Medicine. 6th ed. London: BC Decker; 2003:chap 33, 465-478.

0 0

Post a comment